• Total Unaudited Revenue of $66.1m; +46% growth on FY24
• Unaudited EBITDA of $16.1m; +80% growth on FY24
• 11 PhotonAssay units deployed in FY25 totalling 40 units deployed

Chrysos Corporation Ltd (ASX:C79) ('Chrysos' or the 'Group') announced on 29 July 2025 that it would hold a webinar to announce its full year results on 12 August 2025. The audit of the full year results is ongoing, due to delays associated with completing the audit of international tax positions. Chrysos expects the tax expense to be within the range of $5-10M primarily driven by the impact of the sale of PhotonAssay units to international subsidiaries and expects deferred tax assets not brought to account in international jurisdictions will represent a material portion of this expense. In relation to the Group's FY25 performance, the Board is not aware of any unresolved material matters that will impact the following results. The Board provides commentary on the unaudited results and confirms its guidance for FY26. Total Unaudited Revenue of $66.1m, reflecting 46% growth on FY24 ($45.4m). Unaudited EBITDA of $16.1m, reflecting 80% growth on FY24 ($9.0m). 11 PhotonAssay units were deployed in FY25, bringing the total to 40 units deployed. 9 new leases were signed in FY25, bringing total contracted PhotonAssay units to 59, including a Master Services Agreement and initial lease with Newmont, the world's leading gold miner. Subsequent to year-end, Chrysos has executed four additional agreements, including a strategic partnership with Bureau Veritas, a lease agreement with Newmont for the Merian Gold Mine, an agreement with SGS for delivery of Chrysos' first next-generation 'XN' unit, and an adoption by Pantoro Gold for deployment to the Norseman Gold Mine.

FY26 Guidance: Total Revenue range of $80m to $90m, EBITDA range of $20m to $27m

Chrysos is well-positioned for sustained global growth, with $91.1 million available between cash on hand and undrawn capacity from its debt facility with the Commonwealth Bank of Australia at 30 June 2025.